Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.62 |
| ▸ | NPC1 | O15118 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.54 |
| ▸ | OGG1 | O15527 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17185341 | 0.92 | NPC1 (0.62) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4770266 | 0.92 | NPC1 (0.67) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL2254501 | 0.91 | NPC1 (0.70) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4768172 | 0.91 | NPC1 (0.70) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL2636209 | 0.88 | NAMPT (0.53) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3036579 | 0.88 | HDAC4 (0.56) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL6569206 | 0.86 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL20551505 | 0.85 | NPSR1 (0.54) | RAB9ANPC1SMN1; SMN2CYP1A2HPGD | |
| SCHEMBL28513976 | 0.84 | RAB9A (0.50) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL28512074 | 0.84 | RAB9A (0.50) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115710287-B | Ring-opening boronation reaction method for cyclopropane compound under no metal catalysis | 中国科学院兰州化学物理研究所 | 2024-01-09 | — | — | CN | disclosed |
| CN-115710287-A | Ring-opening boronization reaction method of cyclopropane compound under condition of no metal catalysis | 中国科学院兰州化学物理研究所 | 2023-02-24 | — | — | CN | disclosed |
| WO-2015161011-A1 | BENZAMIDE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-10-22 | — | — | WO | disclosed |
| WO-2015161014-A1 | HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-10-22 | — | — | WO | disclosed |
| US-20100055071-A1 | Anti-Viral Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-20100004441-A1 | N-(5-Membered Aromatic Ring)-Amido Anti-Viral Compounds | SCHMITZ FRANZ ULRICH | 2010-01-07 | — | — | US | disclosed |
| US-7629340-B2 | N-(6-membered aromatic ring)-amido anti-viral compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-7595398-B2 | N-(5-membered aromatic ring)-amido anti-viral compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| EP-2097405-A2 | ANTI-VIRAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20090099160-A1 | 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| CN-101331125-A | N-(5-membered aromatic ring)-amido anti-viral compounds | GENELABS TECH INC (US) | 2008-12-24 | — | — | CN | disclosed |
| EP-1976829-A2 | N-(6-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. (US) | 2008-10-08 | — | — | EP | disclosed |
| EP-1971597-A2 | N-(5-MEMBERED HETEROAROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20080193411-A1 | Anti-viral Compounds | GENELABS TECHNOLOGIES, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008070447-A2 | ANTI-VIRAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
| CN-101115752-A | 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors | ASTRAZENECA AB (SE) | 2008-01-30 | — | — | CN | disclosed |
| US-20070265265-A1 | N-(5-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. | 2007-11-15 | — | — | US | disclosed |
| US-20070265262-A1 | N-(6-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. | 2007-11-15 | — | — | US | disclosed |
| WO-2007070556-A2 | N-(6-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070600-A2 | N-(5-MEMBERED HETEROAROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080193411-A1 | Anti-viral Compounds | ZC3HAV1, ZC3HAV1L, SARS1 | RAB9A 1092/4885NPC1 981/4885SMN1; SMN2 441/4885 |
| US-20090099160-A1 | 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors | CCNI, CDK4, CDK3 | RAB9A 3785/4885NPC1 4535/4885SMN1; SMN2 1922/4885 |
| US-20070265262-A1 | N-(6-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | ZC3HAV1, HAVCR2, ZC3HAV1L | RAB9A 609/4885NPC1 1321/4885SMN1; SMN2 1109/4885 |
| US-20100055071-A1 | Anti-Viral Compounds | ZC3HAV1, ZC3HAV1L, SARS1 | RAB9A 1092/4885NPC1 981/4885SMN1; SMN2 441/4885 |
| US-20100004441-A1 | N-(5-Membered Aromatic Ring)-Amido Anti-Viral Compounds | ZC3HAV1, ZC3HAV1L, HAVCR2 | RAB9A 487/4885NPC1 1259/4885SMN1; SMN2 1431/4885 |
| US-20070265265-A1 | N-(5-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | ZC3HAV1, ZC3HAV1L, HAVCR2 | RAB9A 487/4885NPC1 1259/4885SMN1; SMN2 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.